NewAmsterdam Pharma Company N.V. (NAMS) Key Metrics
NAMS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.37B
- Enterprise value
- $2.08B
- P/E (TTM)
- —
- Forward P/E
- 119.0
- PEG ratio
- —
- Price / sales
- 332.9
- Price / book
- 4.3
- EV / EBITDA
- 27.6
- Dividend yield
- —
- Beta
- 0.10
NAMS key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNAMS valuation Price multiples at each fiscal year-end price.
NAMS returns How much profit the business earns on the capital it uses.
NAMS per-share figures Results divided by the shares outstanding at year-end.
NAMS financial health Debt, liquidity and how easily interest is covered.
NAMS efficiency & capital use Working capital cycle and where the cash goes.
NAMS valuation history
NAMS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NAMS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NAMS price vs earnings per share
NAMS key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Valuation | ||
| Market capitalization | $4.01B | $2.43B |
| Enterprise value | $3.38B | $1.59B |
| Price / sales | 178.3 | 53.2 |
| Price / book | 5.9 | 3.2 |
| EV / sales | 150.1 | 34.9 |
| Earnings yield | −5.1% | −10.0% |
| Free cash flow yield | −3.7% | −6.6% |
| Share price at fiscal year-end | $35.08 | $25.70 |
| Per share | ||
| Revenue per share | $0.20 | $0.48 |
| Earnings per share | −$1.78 | −$2.56 |
| Operating cash flow per share | −$1.29 | −$1.68 |
| Free cash flow per share | −$1.29 | −$1.69 |
| Cash per share | $5.56 | $8.84 |
| Book value per share | $5.97 | $8.03 |
| Tangible book value per share | $5.97 | $8.02 |
| Capex per share | $0.00 | $0.01 |
| Debt per share | $0.00 | $0.00 |
| Shares outstanding | 114.4M | 94.4M |
| Change in shares outstanding | +21.2% | — |
| Returns & profitability | ||
| Return on equity (ROE) | −28.3% | −31.9% |
| Return on assets (ROA) | −24.9% | −27.9% |
| Return on tangible assets | −26.5% | −28.0% |
| Free cash flow margin | −657.8% | −349.5% |
| Financial health | ||
| Total debt | $202,000 | $448,000 |
| Cash & short-term investments | $636.2M | $834.2M |
| Net debt | −$636.0M | −$833.7M |
| Debt / equity | 0.00 | 0.00 |
| Debt / assets | 0.00 | 0.00 |
| Current ratio | 7.88 | 8.08 |
| Quick ratio | 7.88 | 8.08 |
| Working capital | $589.9M | $756.5M |
| Invested capital | $47.4M | −$76.2M |
| Tangible asset value | $683.0M | $757.0M |
| Net current asset value | $589.8M | $756.3M |
| Graham net-net per share | $4.96 | $7.87 |
| Capital allocation | ||
| Capex / revenue | 1.1% | 1.5% |
| Capex / depreciation | 1.12 | 5.95 |
| Stock-based compensation / revenue | 264.1% | 73.8% |
| R&D / revenue | 630.3% | 332.3% |
| SG&A / revenue | 472.4% | 154.6% |
| Efficiency | ||
| Days sales outstanding | 360.5 | 170.7 |
| Days payables outstanding | 42,420.4 | 15,323.5 |
| Cash conversion cycle (days) | -42,059.9 | -15,152.9 |
| Receivables turnover | 1.01 | 2.14 |
| Payables turnover | 0.01 | 0.02 |
| Asset turnover | 0.03 | 0.05 |
| Average receivables | $22.2M | $21.3M |
| Average payables | $6.9M | $4.7M |
| Intangibles / total assets | 0.1% | 0.1% |
Computed from NAMS's annual financial statements (latest annual report filed February 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NAMS valuation and financial ratios
NewAmsterdam Pharma earned a return on equity of −28.3% in fiscal 2025. It ended the year with $0.2 million of debt and $636.2 million in cash and short-term investments, a net cash position of $636.0 million.
See the NAMS income statement, the NAMS chart for price history, or the NAMS stock overview for the latest quote and news.
NAMS key metrics FAQ
What is NewAmsterdam Pharma's return on equity?
NewAmsterdam Pharma's return on equity (ROE) was −28.3% in fiscal 2025: net income of -$203.8 million on average shareholders' equity of $720.5 million.
How much debt does NewAmsterdam Pharma have?
NewAmsterdam Pharma had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is NewAmsterdam Pharma's free cash flow yield?
NewAmsterdam Pharma generated -$148.0 million of free cash flow in fiscal 2025, a free cash flow yield of −3.7% on its market value at year-end ($4.0 billion).
What is NewAmsterdam Pharma's current ratio?
NewAmsterdam Pharma's current ratio was 7.88 at the end of fiscal 2025: current assets were 7.88 times current liabilities.